All articles tagged with #weight regain
New research suggests that fat cells retain an epigenetic 'memory' of obesity, keeping hunger hormones elevated even after weight loss. This biological mechanism may explain why patients regain weight quickly after stopping GLP-1 medications, highlighting the need for long-term metabolic management rather than short-term fixes.
An observational study finds that individuals who regain weight after stopping obesity medications have higher odds of suicidal thoughts. The findings highlight a potential mental health risk associated with weight regain, though causality cannot be established. Clinicians are urged to monitor mood and provide behavioral support during medication discontinuation.
Original GLP-1 weight-loss trials found that most people regain the lost weight after stopping treatment, but three recent studies show that some individuals can maintain weight loss post-discontinuation, underscoring variability and the potential importance of treatment duration and lasting lifestyle changes.
Real-world data show weight loss from GLP-1 therapy is often not sustained after discontinuation, with most patients regaining weight and metabolic benefits fading within about 1.4 years. Emerging strategies—endoscopic approaches such as endoscopic sleeve gastroplasty, duodenal mucosal resurfacing, and the newly approved oral GLP-1 orforglipron—offer potential for longer-term maintenance, but cost, insurance coverage, and access remain barriers. When cost is considered, bariatric surgery can be more cost-effective long term; more head-to-head studies and guidelines are needed to define optimal maintenance after GLP-1 therapy.
A decade-long study shows that obesity can leave a persistent “memory” in both fat and immune cells through DNA methylation, sustaining inflammation and higher risk for obesity-related diseases even after weight loss. Maintaining weight loss for about five to ten years may gradually erode this memory, underscoring why relapse is common and highlighting potential therapies such as SGLT2 inhibitors to reverse obesity’s immune effects.
A meta-analysis of six randomized trials (3,200+ participants) shows people rapidly regain about 60% of the weight lost during GLP-1 class obesity treatments within a year of stopping, with long-term modelling suggesting regain may plateau after around 60 weeks and reach roughly 75% of the lost weight. The studies raise uncertainty about whether regained weight is lean mass or fat, and they underscore the potential need for tapering doses and lifestyle support to preserve fat loss after cessation.
A Wall Street Journal piece explains that GLP-1 weight-loss medications like Ozempic and Wegovy are intended as lifelong treatments for obesity, not quick lifestyle fixes; studies show most people who stop the drugs regain the lost weight within about 1.5 years, underscoring the need for ongoing treatment and monitoring.
Real-world data cited by Reuters via Fresh Stock Ideas suggests a sizable share of patients using Novo Nordisk and Eli Lilly GLP-1 obesity drugs may maintain weight loss for months after discontinuing the treatment.
Stopping GLP-1 weight-loss drugs causes weight regain four times faster than ending exercise, with most individuals returning to their original weight within 18 months, highlighting the need for long-term management strategies.
A study shows that individuals who stop using GLP-1 drugs like Ozempic and Wegovy tend to regain their lost weight within about 18 months, and those who used these drugs regain weight four times faster than those relying solely on diet and exercise. For long-term health benefits, lasting lifestyle changes are essential.
A review of research indicates that individuals who stop using GLP-1 drugs like Ozempic and Wegovy for weight loss tend to regain their lost weight within approximately 18 months, and this regain occurs faster than with behavioral methods like dieting or exercise. To maintain health benefits after discontinuing these medications, lasting lifestyle changes are essential.
Doctors warn that weight-loss drugs like Ozempic and Wegovy, originally for diabetes, carry risks such as side effects and potential weight regain after stopping, emphasizing the importance of lifestyle changes and caution against viewing these medications as quick fixes.
Research warns of dangers associated with starting and stopping weight loss shots like Semaglutide, including serious side effects, potential for weight regain, and muscle loss. Medical professionals emphasize the importance of understanding risks, addressing underlying health issues, and adopting sustainable lifestyle changes to maintain weight loss long-term. A special offer for a comprehensive health assessment is available at Health Utah.
A study found that weight lost through anti-obesity medications like Ozempic tends to be regained after stopping treatment, with significant weight returning within 8 to 20 weeks, highlighting challenges in maintaining weight loss post-medication.
A study reviewing 11 research papers found that weight loss achieved through anti-obesity medications like Ozempic often reverses within weeks after stopping the drugs, with an average regain of 2.5 kg over 20 weeks, highlighting challenges in maintaining weight loss post-treatment.